Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.
暂无分享,去创建一个
M. Rocco | C. Langefeld | J. Divers | D. Bowden | B. Freedman | P. Hicks | J. Parks | P. Antinozzi | Lijun Ma | M. Murea | J. Otvos | Jolyn Turner
[1] C. Langefeld,et al. Response to Mechanism of Action of APOL1 in Renal Allograft Survival (and Native CKD) Remains Unclear , 2011 .
[2] M. Rocco,et al. The APOL1 Gene and Allograft Survival after Kidney Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] R. Krauss,et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. , 2011, Clinical chemistry.
[4] B. Freedman,et al. Lipotoxicity in diabetic nephropathy: the potential role of fatty acid oxidation. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[5] Keith C. Norris,et al. Intensive blood-pressure control in hypertensive chronic kidney disease. , 2010, The New England journal of medicine.
[6] C. Winkler,et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. , 2010, Journal of the American Society of Nephrology : JASN.
[7] C. Winkler,et al. Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.
[8] S. Rosset,et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene , 2010, Human Genetics.
[9] B. Freedman,et al. The spectrum of MYH9-associated nephropathy. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[10] B. Freedman,et al. Essential hypertension and risk of nephropathy: a reappraisal , 2010, Current opinion in nephrology and hypertension.
[11] C. Langefeld,et al. Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] Amanda L. Brown,et al. Apolipoprotein M expression increases the size of nascent preβ HDL formed by ATP binding cassette transporter A1 , 2010, Journal of Lipid Research.
[13] C. Winkler,et al. Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15 , 2010, Human molecular genetics.
[14] C. Winkler,et al. Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] Yongmei Liu,et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. , 2009, Kidney international.
[16] M. Leppert,et al. Polymorphisms in the Nonmuscle Myosin Heavy Chain 9 Gene (MYH9) Are Associated with Albuminuria in Hypertensive African Americans: The HyperGEN Study , 2009, American Journal of Nephrology.
[17] D. Reich,et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans , 2008, Nature Genetics.
[18] D. Vlahov,et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis , 2008, Nature Genetics.
[19] Donald W. Bowden,et al. Exploration of the utility of ancestry informative markers for genetic association studies of African Americans with type 2 diabetes and end stage renal disease , 2008, Human Genetics.
[20] Keith C. Norris,et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. , 2008, Archives of internal medicine.
[21] L. Kuller,et al. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. , 2007, Atherosclerosis.
[22] B. Dahlbäck,et al. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma Published, JLR Papers in Press, May 25, 2007. , 2007, Journal of Lipid Research.
[23] W. Cromwell,et al. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. , 2006, Clinics in laboratory medicine.
[24] M. Salvadori,et al. FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1‐Year, Randomized Controlled Trial in Europe and Australasia , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[25] M. Hayden,et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. , 2005, The Journal of clinical investigation.
[26] Philip F Halloran,et al. Immunosuppressive drugs for kidney transplantation. , 2004, The New England journal of medicine.
[27] J. Cyster,et al. FTY720: Sphingosine 1‐Phosphate Receptor‐1 in the Control of Lymphocyte Egress and Endothelial Barrier Function , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[28] R. Ferguson. FTY720 immunomodulation: optimism for improved transplant regimens. , 2004, Transplantation proceedings.
[29] T. Orchard,et al. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 Diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study , 2003, Diabetologia.
[30] C. Marcantoni,et al. Hypertensive nephrosclerosis in African Americans versus Caucasians. , 2002, Kidney international.
[31] M. Jauhiainen,et al. The Mechanism of the Remodeling of High Density Lipoproteins by Phospholipid Transfer Protein* , 2001, The Journal of Biological Chemistry.
[32] P. Barter,et al. Remodelling of high density lipoproteins by plasma factors. , 1999, Atherosclerosis.
[33] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[34] P. Duchateau,et al. Apolipoprotein L, a New Human High Density Lipoprotein Apolipoprotein Expressed by the Pancreas , 1997, The Journal of Biological Chemistry.
[35] B. Freedman,et al. The link between hypertension and nephrosclerosis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[36] L. Kuller,et al. Lipoprotein subclass and particle size differences in Afro-Caribbeans, African Americans, and white Americans: associations with hepatic lipase gene variation. , 2006, Metabolism: clinical and experimental.
[37] D. Freedman,et al. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. , 2002, Atherosclerosis.
[38] J. Breyer,et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. , 1997, Kidney international.
[39] B. Freedman,et al. Renal biopsy findings in presumed hypertensive nephrosclerosis. , 1994, American journal of nephrology.